Microcap Ledger

Tickers · $BNTC

Benitec Biopharma Inc. $BNTC

By Microcap Ledger desk · CIK 0001808898

Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange
Nasdaq Capital Market
Sector
Pharmaceutical Preparations
Headquarters
Hayward, CA
Fiscal year end
June 30
Shares outstanding
34,882,726 [10-K 2026-09-14]
as of 2026-09-04

Sources: [10-K 2026-09-14]

What the company doesAI summary of filing

Benitec Biopharma Inc. is a clinical-stage biotechnology company developing gene therapy products based on its proprietary ddRNAi and silence-and-replace technology platform. The company's lead product candidate, BB-301, is an AAV-based gene therapy designed to treat Oculopharyngeal Muscular Dystrophy (OPMD) by permanently silencing the disease-causing PABPN1 gene and simultaneously replacing it with a functional version, with the first patient dosed in a Phase 1b/2a clinical trial in November 2023. BB-301 has received Orphan Drug Designation and Fast Track Designation in the United States and Orphan Drug Designation in the European Union. The company is pre-revenue and currently advancing BB-301 through clinical development while exploring potential collaborations with larger biopharmaceutical companies for future co-development and commercialization. [10-K 2026-09-14]

Segments: BB-301 (OPMD treatment)

Financial health

From XBRL company facts (USD)
PeriodRevenueNet incomeOperating cash flowCashFiling
FY ended Jun 2026—−$45.55M −$16.52M$179.97M[10-K 2026-09-14]
FY ended Jun 2025—−$37.92M −$23.59M$97.74M[10-K 2026-09-14]
Quarterly cash burn
−$4.13M

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
DateShares outstandingFiling
2024-11-1223,216,425[10-Q 2024-11-14]
2025-02-1423,451,475[10-Q 2025-02-14]
2025-05-1425,600,210[10-Q 2025-05-14]
2025-09-1726,250,469[10-K/A 2026-03-20]
2025-11-1433,862,226[10-Q 2025-11-14]
2026-02-0634,354,334[10-Q 2026-02-12]
2026-05-0434,354,334[10-Q 2026-05-14]
2026-09-0434,882,726[10-K 2026-09-14]
Shelf registration
S-3 filed 2026-09-14; declared effective 2026-09-21 [S-3 2026-09-14]

Listing status

Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
DateInsiderTypeSharesPriceFiling
2026-06-29Buchi J Kevinother51,813—[4 2026-06-30]
2025-12-29Suvretta Capital Management, Llcbuy65,800$13.44[4 2025-12-29]
2025-12-29Suvretta Capital Management, Llcbuy11,587$13.44[4 2025-12-29]
2025-12-26Suvretta Capital Management, Llcbuy14,320$13.10[4 2025-12-29]
2025-12-26Suvretta Capital Management, Llcbuy2,516$13.10[4 2025-12-29]
2025-12-23Suvretta Capital Management, Llcbuy42,600$12.85[4 2025-12-29]
2025-12-23Suvretta Capital Management, Llcbuy7,400$12.85[4 2025-12-29]
2025-12-22Suvretta Capital Management, Llcbuy16,650$12.08[4 2025-12-22]
2025-12-22Suvretta Capital Management, Llcbuy2,892$12.08[4 2025-12-22]
2025-12-19Suvretta Capital Management, Llcbuy13,950$11.48[4 2025-12-22]
2025-12-19Suvretta Capital Management, Llcbuy2,434$11.48[4 2025-12-22]
2025-12-18Suvretta Capital Management, Llcbuy8,700$11.24[4 2025-12-22]

Catalysts and calendar

Recent filings and releases
DateTypeTitle
2026-10-058-KRegulation FD disclosure
2026-09-308-KAuditor change
2026-09-248-KAuditor change
2026-09-14S-3Registration statement
2026-09-1410-KAnnual report
2026-09-148-KResults of operations
2026-05-298-KDirector or officer change
2026-05-1410-QQuarterly report
2026-05-148-KResults of operations
2026-03-2010-K/AAmended report
2026-02-128-KResults of operations
2026-02-1210-QQuarterly report

Facts as of . Small caps move fast; check the latest filings.